OXiGENE Schedules First Quarter 2007 Earnings Conference Call

OXiGENE Schedules First Quarter 2007 Earnings Conference Call

Live Internet Webcast to be Available at www.oxigene.com

    WALTHAM, Mass.--(BUSINESS WIRE)--April 18, 2007--Regulatory News:


    OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a clinical-stage
biotechnology company developing novel therapeutics to treat cancer
and eye diseases, will announce its first quarter 2007 results on
Wednesday, April 25, 2007 prior to the opening of the NASDAQ Stock
Market, followed by a conference call at 10:00 a.m. ET. OXiGENE's
President and Chief Executive Officer, Dr. Richard Chin, Chief
Scientific Officer, Dr. David Chaplin, Chief Medical Officer, Dr.
Peter Harris, Chief Business Officer, John Kollins and James Murphy,
Chief Financial Officer, will host the call.

    To listen to a live or an archived version of the audio webcast,
please log on to the Company's website, www.oxigene.com. Under the"Investor Center" tab, click on the link to "Presentations &
Conference Calls."

    OXiGENE's earnings conference call can also be heard live by
dialing (800) 565-5442 in the United States and Canada, and (913)
312-1298 for international callers, five minutes prior to the
beginning of the call. A replay will be available starting at 1:00
p.m. ET on April 25, 2007 and ending at midnight ET on Tuesday, May 1,
2007. To access the replay, please dial (888) 203-1112 if calling from
the United States or Canada, or (719) 457-0820 from international
locations. Please refer to replay pass code 2246765.

    About OXiGENE, Inc.

    OXiGENE is a clinical-stage biotechnology company developing novel
small-molecule therapeutics to treat cancer and eye diseases. The
Company's major focus is the clinical advancement of drug candidates
that selectively disrupt abnormal blood vessels associated with solid
tumor progression and visual impairment. OXiGENE is dedicated to
leveraging its intellectual property position and therapeutic
development expertise to bring life saving and enhancing medicines to
patients.


OXiGENE, Inc.
Investor Relations
781-547-5900
info@oxigene.com